Key Highlights

  • Argent BioPharma entered two Loan facilities of up to US$250,000 each, US$500,000 in aggregate, to fund working capital, corporate costs and research and development.
  • Each Facility is unsecured with a nine-month repayment term and a repayment amount of US$287,500, with no ongoing interest.
  • Each lender can require repayment within 15 Business days if Argent completes a third-party capital raise of at least A$5.0 million.

Argent BioPharma Ltd (ASX:RGT) announced on 1 October 2026 that it has entered into two loan facility agreements with WVP Emerging Manager Onshore Fund LLC, acting for C/M Capital Series, and C/M Capital Master Fund, LP. Each lender has agreed to provide a facility of up to US$250,000, US$500,000 in aggregate.

Purpose of the funds

Argent says proceeds will be used for working capital, covering corporate costs and Research and Development activities. The announcement does not describe any specific project or milestone funded by the loans.

Key terms

Each facility is a non-revolving Cash Advance facility with a single drawdown and a limit of US$250,000. Each is subject to a nine-month repayment term after drawdown, or another date agreed in writing, and the repayment amount is US$287,500 per facility, with no ongoing interest charges. The facilities are unsecured. Overdue amounts attract default interest of 18% a year.

The repayment amount exceeds the amount advanced by US$37,500 per facility, equal to 15% of the US$250,000 limit, and the release does not describe that difference as interest.

Early repayment trigger

If Argent completes a capital raise of at least A$5.0 million from third parties, each lender may require repayment within 15 business days of written notice. Funds advanced under the existing Convertible Securities Agreements are excluded from that calculation. This means that a successful larger raise could bring forward repayment of the loans.

Lender relationships and company profile

Each lender is already a counterparty to a convertible securities agreement with Argent. In connection with the loans, each lender consented to Argent incurring this Debt and waived its rights under the relevant provisions of those agreements. Argent states the lenders are not related parties or substantial holders of the company.

Argent describes itself as a revenue-generating specialty biopharmaceutical company built around CimetrA, a first-in-class immune-modulating platform for inflammatory and autoimmune diseases, with NanoBodies, peptide technologies and EU-GMP manufacturing. Following the global licensing of CannEpil, it has adopted a capital-efficient strategy combining proprietary IP, commercial-stage products, licensing, Manufacturing services and Royalty income.

Cost of the facilities

Against a combined limit of US$500,000, the two facilities carry a combined repayment amount of US$575,000, which is US$75,000 more than the amount advanced if both are fully drawn. The company describes the arrangement as having no ongoing interest charges, so the cost is embedded in the fixed repayment figure. Default interest of 18% a year applies only to overdue amounts.

Funding context

The loans sit alongside existing convertible securities agreements with the same lenders, who agreed to waive the relevant provisions so that the new debt could be incurred. Argent describes a strategy centred on immune-modulation intellectual property, commercial-stage products, strategic licensing, manufacturing services and royalty income, following the global licensing of CannEpil, and describes a pathway towards expansion into US capital markets. The announcement was authorised by the Board.